10 Best Very Cheap Stocks To Buy Right Now

7. Pfizer Inc. (NYSE:PFE)

P/E Ratio: 8.68

Average Analysts Upside: 19.47%

Pfizer Inc. (NYSE:PFE) is a leading American pharmaceutical company that is engaged in the discovery, manufacturing, marketing, and sale and distribution of related products worldwide. The biopharmaceutical isn’t generating the massive growth it was during the COVID-19 and post-COVID period as the company’s COVID-related revenue has been declining. But Pfizer’s overall business is growing and the fundamentals reflect an optimistic future about the company moving forward.

The COVID-19 vaccine sales dropped by 52% year-over-year to $5.4 billion for the full year 2024. However, the company’s top-line sales soared over 7% year-over-year. Pfizer’s specialty care segment posted 11% growth, and its oncology business expanded at a rate of 25%, driven by the acquisition of Seagen, which generated around $3.4 billion in revenue. Despite the decline in COVID-related sales, the company’s primary care business, which includes Comirnaty, only dropped by 2% from a year ago.

On February 11, Jefferies analyst Akash Tewari raised the price target on PFE shares from $33 to $34, keeping a Buy rating. The upgrade follows Pfizer’s releasing abstract on mevrometostat from the American Society of Clinical Oncology Genitourinary symposium. Tewari estimates mevrometostat’s risk-adjusted peak sales of approximately $1.2 billion. The analyst also remains optimistic about Pfizer Inc.’s (NYSE:PFE) oncology segment.